US FDA Restricts JAK Inhibitors To Second-Line In Rheumatoid Arthritis Amid CV, Cancer, Mortality Risks

 
• By Derrick Gingery
  
rheumatoid arthritis x-ray image
A postmarket study of the rheumatoid arthritis drug Xeljanz lead the FDA to revise the boxed warning and limit its use. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Post-Marketing Regulation & Studies

More from Product Reviews